Extracting Beneath the Surface
Traditional approaches that profile the immune response typically rely on the isolation and nucleotide sequencing of circulating B-cells. Although these approaches are still important, they may not completely reflect the full antibody-protein repertoire and may provide a superficial account of the immune response.
Rapidly Mine the Immune Response.
NovorIg™ rapidly mines the immune response with greater depth. By exploiting our proteomics and bioinformatics, NovorIg™ decodes the exact immune response at specific time points by mining the antibody repertoire in great depth with a combined analysis of the B-cells and antibody proteins.
Reproducibility impacts.
Who uses MATCHmAb™.
Researchers, Antibody Users
Researchers use tool antibodies every day, across many applications. Sequence confirmation is the first step in troubleshooting, or daily quality checks to prevent issues.
Antibody Venders, Producers
Easily verify each new lot. Offer premium Verified by MATCHmAb™ products, or an add-on service.
Antibody Engineering
Cell line instability could introduce mutations to humanized antibodies. Verify the CDRs have not changed or confirm the full expressed sequence matches the engineered one.
CRO, Custom Developers
Checkpoints to increase confidence. Avoid troubleshooting re-runs with clients.
How NovorIg™ Works.
| MATCHmAb™ | |
|---|---|
| Workflow | LC-MS/MS, single or dual digest |
| Bioinformatics | Real-time analysis, purpose built algorithms |
| Speed | Fast: 1-4 days |
| Throughput | High: > 100 per week |
| Coverage | Higher, and amino acid level |
| Traditional Peptide Mapping | |
|---|---|
| Workflow | LC-MS only, single enzyme only |
| Bioinformatics | Post-processing, off the shelf tools |
| Speed | Slow: weeks |
| Throughput | Low |
| Coverage | Lower, and only peptide level |
Enhanced Examination.
NovorIg™ offers researchers the ability to enhance their examination of the humoral immune response in different conditions including immunity cohort studies for disease diagnosis and prognosis by exploiting the biomarker nature of the antibody repertoire.
Talk to Our Scientists.
We Have Sequenced 6000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Antibody Sequencing, Discovery and Proteomics Services.
Antibody Sequencing & Discovery Services.
REmAb®
Monoclonal antibody sequencing from small protein samples, no need for hybridoma or DNA information. Full sequence in record time.
Explore REmAb
REpAb®
Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Explore REpAb
MATCHmAb™
Antibody verification by real-time peptide mapping. Antibody sequence confirmation service for reproducibility.
Explore MATCHmAb
HDX-MS
Mass spec based epitope mapping. Epitope mapping for identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.
Explore Epitope Mapping
SPR Analysis
Label-free evaluation of antibody-antigen binding relies on a Surface Plasmon Resonance technology. Combined with our expertise in antibody interactions, this results in high sensitivity and the lowest noise even in complex analytes.
Explore SPR Analysis
NovorIg™
Quantify the immune response by accurately profiling the vast antibody-protein repertoire and its different isotypes, and subtypes in serum over time.
Explore Immune Response Profiling
We Have Sequenced 4000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics